Research Library · Compound Guide
Retatrutide (LY3437943): Research Overview & Molecular Profile
Retatrutide, also known by its development code LY3437943, is a synthetic peptide studied in preclinical research as a triple-receptor agonist - in laboratory models it interacts with three receptors: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). It is among the most widely referenced research peptides in the current scientific literature. AurexBioLabs supplies Retatrutide strictly as a lyophilized research compound for in vitro and animal-model laboratory study only, third-party tested with a Certificate of Analysis on every batch.
For Research Use Only. Not for human or veterinary use. Not a drug, food, or cosmetic. This page is educational reference material for qualified researchers and contains no medical advice, dosing, or health claims.
Important: Retatrutide is an investigational compound that has been the subject of clinical trials. It is not an FDA-approved product, and the material supplied by AurexBioLabs is a research-grade compound sold strictly for laboratory research use - it is not for human or veterinary use of any kind.
Retatrutide Molecular Profile
| Compound type | Synthetic peptide, triple-receptor agonist (research classification) |
|---|---|
| Development code | LY3437943 |
| Receptor targets (research models) | GCGR, GIPR, GLP-1R |
| Molecular weight | ~4731.3 Da |
| CAS number | 2381089-83-2 |
| Physical form | Lyophilized white powder |
Research Context
In the published preclinical and investigational literature, Retatrutide is characterized as a triple agonist studied in laboratory models of the GCGR, GIPR, and GLP-1R signaling pathways. Research has examined its receptor-binding characteristics across these three targets. Retatrutide is an investigational compound and has not been approved by the FDA for any use. All findings referenced here are confined to laboratory and clinical-research literature; researchers should consult primary sources (e.g. peer-reviewed journals and clinical-trial registries) directly for methodology and results.
How Retatrutide Compares to Single-Receptor Peptides
A frequent focus in the literature is Retatrutide's classification as a triple-receptor agonist, versus single-receptor (GLP-1R only) or dual-receptor research peptides. This triple-target profile is what distinguishes it as a discrete research compound.
Handling & Laboratory Considerations
Storage
Lyophilized Retatrutide is stored frozen and protected from light.
Reconstitution (research context)
Prepared with bacteriostatic or sterile water per the researcher's protocol; reconstituted solution is refrigerated.
Stability
Minimize freeze-thaw and exposure to heat and light.
Quality & Verification at AurexBioLabs
Every batch of research-grade Retatrutide is third-party HPLC and mass-spec verified with a published Certificate of Analysis. Confirm your vial by lot number at our verification page.
Frequently Asked Questions
Approximately 4731.3 Da.
2381089-83-2.
Its development code is LY3437943.
In laboratory models it is characterized as a triple agonist of the glucagon receptor (GCGR), GIP receptor (GIPR), and GLP-1 receptor (GLP-1R).
Yes - HPLC and mass-spec verified with a Certificate of Analysis for every batch.
No. It is an investigational compound; AurexBioLabs supplies it as a research-grade compound for laboratory use only, not for human use.
Next Steps
Verification & catalog
For Research Use Only. Not for human or veterinary use. Not a drug, food, or cosmetic. This page is educational reference material for qualified researchers and contains no medical advice, dosing, or health claims.
Retatrutide is sold for laboratory research use only. It is an investigational compound and is not for human or veterinary use, diagnostic, or therapeutic purposes.